The US Food and Drug Administration has dialed back its recommendations on statistical approaches to comparative analytical assessments in a move aimed at giving biosimilar sponsors more flexibility.
A new draft guidance released on 21 May describes the use of quality range testing in lieu of statistical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?